TY - JOUR
T1 - Teprotumumab and Hearing Loss
T2 - Case Series and Proposal for Audiologic Monitoring
AU - Belinsky, Irina
AU - Creighton, Francis X.
AU - Mahoney, Nicholas
AU - Petris, Carisa K.
AU - Callahan, Alison B.
AU - Campbell, Ashley A.
AU - Kazim, Michael
AU - Lee, H. B.Harold
AU - Yoon, Michael K.
AU - Dagi, Lora R.Glass
N1 - Funding Information:
The Departments of Ophthalmology at Columbia University Irving Medical Center and NYU Langone Health are supported by an unrestricted grant from Research to Prevent Blindness.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Purpose: To present a protocol for audiologic monitoring in the setting of teprotumumab treatment of thyroid eye disease, motivated by 4 cases of significant hearing loss, and review the relevant literature. Methods: Cases of hearing loss in the setting of teprotumumab were retrospectively elicited as part of a multi-institutional focus group, including oculoplastic surgeons, a neurotologist and an endocrinologist. A literature review was performed. Results: An aggregate of 4 cases of teprotumumab-associated hearing loss documented by formal audiologic testing were identified among 3 clinicians who had treated 28 patients. Conclusions: Teprotumumab may cause a spectrum of potentially irreversible hearing loss ranging from mild to severe, likely resulting from the inhibition of the insulin-like growth factor-1 and the insulin-like growth factor-1 receptor pathway. Due to the novelty of teprotumumab and the lack of a comprehensive understanding of its effect on hearing, the authors endorse prospective investigations of hearing loss in the setting of teprotumumab treatment. Until the results of such studies are available, the authors think it prudent to adopt a surveillance protocol to include an audiogram and tympanometry before, during and after infusion, and when prompted by new symptoms of hearing dysfunction.
AB - Purpose: To present a protocol for audiologic monitoring in the setting of teprotumumab treatment of thyroid eye disease, motivated by 4 cases of significant hearing loss, and review the relevant literature. Methods: Cases of hearing loss in the setting of teprotumumab were retrospectively elicited as part of a multi-institutional focus group, including oculoplastic surgeons, a neurotologist and an endocrinologist. A literature review was performed. Results: An aggregate of 4 cases of teprotumumab-associated hearing loss documented by formal audiologic testing were identified among 3 clinicians who had treated 28 patients. Conclusions: Teprotumumab may cause a spectrum of potentially irreversible hearing loss ranging from mild to severe, likely resulting from the inhibition of the insulin-like growth factor-1 and the insulin-like growth factor-1 receptor pathway. Due to the novelty of teprotumumab and the lack of a comprehensive understanding of its effect on hearing, the authors endorse prospective investigations of hearing loss in the setting of teprotumumab treatment. Until the results of such studies are available, the authors think it prudent to adopt a surveillance protocol to include an audiogram and tympanometry before, during and after infusion, and when prompted by new symptoms of hearing dysfunction.
UR - http://www.scopus.com/inward/record.url?scp=85113699181&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113699181&partnerID=8YFLogxK
U2 - 10.1097/IOP.0000000000001995
DO - 10.1097/IOP.0000000000001995
M3 - Article
C2 - 34085994
AN - SCOPUS:85113699181
SN - 0740-9303
VL - 38
SP - 73
EP - 78
JO - Ophthalmic plastic and reconstructive surgery
JF - Ophthalmic plastic and reconstructive surgery
IS - 1
ER -